secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-12-31T23:59:59+00:00
Accession:  0001104659-25-125309
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem discontinues RAMP 203 (KRAS G12C) trial; pivots to VS-7375 for KRAS G12D
--------------------------------------------------------------------------------

- Discontinues RAMP 203 (KRAS G12C) trial in advanced NSCLC; focuses on VS-7375 (KRAS G12D inhibitor).
- As of Nov 26, 2025: doublet in G12C-naive patients achieved ORR 40% (12/30), mPFS 11.1 months.
- Previously G12C-treated patients in doublet: ORR 9.5% (2/21), mPFS 3.7 months.
- Triplet combo: ORR 50% (2/4) in naive; 36% (4/11) tumor reduction in pretreated.
- VS-7375 showed 69% ORR (11/16) in KRAS G12D NSCLC; no DLTs observed across RAMP 203.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925125309/0001104659-25-125309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925125309/tm2534532d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-125309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer